Home / Market News / $DXCM

$DXCM news and market catalysts

The 30 most recent market catalysts affecting $DXCM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

30 catalysts 4 high impact 24 bullish 1 bearish Medical Devices
Nov 17, 2026 Corporate Catalyst Bearish Impact 65
Dexcom Faces Public Outcry and Legal Challenges Over In-App Data Terms
Dexcom has implemented mandatory in-app terms requiring continuous data sharing, leading to public outcry and legal challenges from the diabetes community. This matters because it …
Nov 9, 2026 Corporate Catalyst Bullish Impact 65
Health Canada Approves Dexcom G7 Integration with myLoop
Health Canada has approved the integration of the Dexcom G7 Continuous Glucose Monitoring (CGM) system with the myLoop automated insulin delivery system, powered by CamAPS FX. This…
Oct 31, 2026 Corporate Catalyst Neutral Impact 65
Multiple Analysts Update Price Targets for DexCom, Inc.
Following its third-quarter earnings, DexCom received several price target upgrades from prominent analysts. UBS, Barclays, Canaccord Genuity, and StoneX all maintained Buy/Overwei…
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
UBS Adjusts DexCom Price Target to $107 From $102, Maintains Buy Rating
UBS updated its outlook on DexCom after the company's Q3 2026 earnings report, raising its price target to $107 from $102 and reaffirming a Buy rating. This indicates a positive se…
Oct 30, 2026 Corporate Catalyst Neutral Impact 65
Analysts Adjust Price Targets for DexCom, Inc.
Raymond James and Barclays have both raised their price targets for DexCom, Inc. stock, moving to $97 from $94 and $120 from $115, respectively. This positive re-evaluation by anal…
Oct 29, 2026 Corporate Catalyst Bullish Impact 85
DexCom Reports Q3 2026 Financial Results and Raises Revenue Guidance
DexCom announced Q3 2026 revenue of $1.34 billion, surpassing the FactSet consensus of $1.33 billion, and adjusted EPS of $0.73, beating estimates of $0.67. This strong performance…
Oct 28, 2026 Corporate Catalyst Neutral Impact 55
Dexcom Announces Canadian Launch of G7 15-Day Continuous Glucose Monitoring System
Dexcom announced the upcoming Canadian launch of its G7 15-Day Continuous Glucose Monitoring System, targeting adults with diabetes. This is a positive development for Dexcom as it…
Oct 12, 2026 Corporate Catalyst Bullish Impact 55
BTIG Maintains Buy on DexCom, Raises Price Target to $96
BTIG analyst Ryan Zimmerman maintained a 'Buy' rating on DexCom (DXCM) and raised the price target from $90 to $96. This action signals continued analyst confidence in DexCom's bus…
Oct 7, 2026 Corporate Catalyst Neutral Impact 65
Barclays Initiates Coverage On DexCom with Overweight Rating, Announces Price Target of $115
Barclays analyst Christopher Pasquale has initiated coverage on DexCom (DXCM) with an 'Overweight' rating and a $115 price target. This event is significant as new analyst coverage…
Oct 1, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on DexCom, Raises Price Target to $105
RBC Capital analyst Kendall Au maintained an 'Outperform' rating on DexCom and raised the price target from $90 to $105. This action signals continued confidence from a prominent f…
Sep 18, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on DexCom, Raises Price Target to $102
Truist Securities analyst Richard Newitter maintained a 'Buy' rating on DexCom (DXCM) and raised the price target from $93 to $102. This action indicates a strengthened positive ou…
Sep 14, 2026 Corporate Catalyst Neutral Impact 65
Dexcom Announces Promotion Of CFO Jereme Sylvain To COO, Retaining CFO Role
This leadership change at Dexcom is a moderate corporate catalyst. While the promotion of a CFO to COO suggests a strong understanding of the company's financial and operational in…
Aug 4, 2026 Corporate Catalyst Bullish Impact 55
Argus Research Maintains Buy on DexCom, Raises Price Target to $96
Argus Research analyst Steve Silver maintained a 'Buy' rating on DexCom (DXCM) and raised the price target from $86 to $96. This action signals increased confidence from a research…
Aug 3, 2026 Corporate Catalyst Bullish Impact 55
Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $90
Canaccord Genuity analyst William Plovanic has maintained a 'Buy' rating on DexCom (DXCM) and raised the price target from $82 to $90. This indicates a positive outlook from a prom…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Citigroup Maintains Buy on DexCom, Raises Price Target to $88
Citigroup analyst Joanne Wuensch has maintained a 'Buy' rating on DexCom and raised the price target from $84 to $88. This action signals continued bullish sentiment from a major f…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on DexCom, Raises Price Target to $90
RBC Capital's analyst Kendall Au has maintained an 'Outperform' rating for DexCom (DXCM) and raised the price target from $85 to $90. This action signals continued confidence in th…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Mizuho Maintains Outperform on DexCom, Raises Price Target to $95
Mizuho analyst Anthony Petrone maintained an 'Outperform' rating on DexCom (DXCM) and raised the price target from $90 to $95. This action signals continued bullish sentiment from …
Jul 31, 2026 Corporate Catalyst Bullish Impact 92
DexCom shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance. Also, multiple analysts raised their respective price targets on the stock.
This headline represents a major positive corporate catalyst for DexCom. The better-than-expected Q2 results and, more importantly, the raised FY26 sales guidance signal strong und…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Piper Sandler Reiterates Overweight on DexCom, Raises Price Target to $95
Piper Sandler analyst Matt O'Brien reiterated an 'Overweight' rating on DexCom (DXCM) and raised the price target from $88 to $95. This action signals continued analyst confidence …
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Wells Fargo Maintains Overweight on DexCom, Raises Price Target to $90
Wells Fargo analyst Larry Biegelsen has maintained an 'Overweight' rating on DexCom and raised the price target from $85 to $90. This action signals continued confidence in DexCom'…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Stifel Maintains Buy on DexCom, Raises Price Target to $95
Stifel analyst Jonathan Block maintained a 'Buy' rating on DexCom and raised the price target from $90 to $95. This action signals an analyst's increased optimism regarding DexCom'…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Benchmark Maintains Buy on DexCom, Raises Price Target to $82
Benchmark analyst Bruce D. Jackson maintained a 'Buy' rating on DexCom and raised the price target from $77 to $82. This action reflects an analyst's updated positive outlook on th…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on DexCom, Raises Price Target to $93
Truist Securities analyst Richard Newitter maintained a 'Buy' rating on DexCom (DXCM) and raised the price target from $87 to $93. This action signals continued bullish sentiment f…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
BTIG Maintains Buy on DexCom, Raises Price Target to $90
BTIG analyst Marie Thibault maintained a 'Buy' rating on DexCom and raised the price target from $80 to $90. This action signals continued analyst confidence in DexCom's future per…
Jul 30, 2026 Corporate Catalyst Bullish Impact 85
DexCom shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance.
This headline is a significant corporate catalyst for DexCom, directly impacting its stock price positively due to better-than-expected financial performance and optimistic future …
Jul 30, 2026 Corporate Catalyst Bullish Impact 75
DexCom Raises FY2026 Sales Guidance from $5.160B-$5.250B to $5.180B-$5.250B vs $5.224B Est
DexCom (DXCM) has updated its fiscal year 2026 sales guidance, raising the lower bound of its previous range from $5.160 billion to $5.180 billion, while keeping the upper bound at…
Jul 30, 2026 Corporate Catalyst Bullish Impact 92
DexCom Q2 Adj. EPS $0.70 Beats $0.61 Estimate, Sales $1.308B Beat $1.290B Estimate
DexCom announced its Q2 earnings, significantly surpassing analyst expectations. The company reported adjusted EPS of $0.70, beating the $0.61 estimate by 14.75%, and sales of $1.3…
Jul 16, 2026 Corporate Catalyst Bullish Impact 75
DexCom shares are trading higher after Truist Securities raised its price target on the stock from $80 to $87.
This headline indicates a positive corporate catalyst for DexCom. An analyst raising a price target suggests a more optimistic outlook on the company's fundamentals, product pipeli…
Jul 16, 2026 Corporate Catalyst Bullish Impact 55
Truist Securities Maintains Buy on DexCom, Raises Price Target to $87
Truist Securities analyst Richard Newitter has updated his coverage on DexCom, maintaining a 'Buy' rating and raising the price target from $80 to $87. This action signals increase…
Jul 15, 2026 Corporate Catalyst Bullish Impact 55
Mizuho Maintains Outperform on DexCom, Raises Price Target to $90
Mizuho analyst Anthony Petrone maintained an 'Outperform' rating on DexCom (DXCM) and raised the price target from $85 to $90. This action signals continued confidence in DexCom's …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.